A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis

Trial Profile

A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Acronyms TITRATION
  • Sponsors Biogen
  • Most Recent Events

    • 20 Nov 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 04 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 30 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top